Cagent Vascular published a case report by Dr. Ajit Rao on Serration Remodeling Therapy (SRT) for AV fistula treatment.

Public source

Publisher name

Public post

Conventional PTA remains the standard for AV fistula and graft dysfunction, but elastic recoil, flow-limiting dissections, and early restenosis keep force repeat interve…

Log in to read the full post

Company

Cagent Vascular

It’s time for a new standard of care. It’s time for Serranator.

Industry
Medical Equipment Manufacturing
Location
Wayne, US
Company size
51–200 employees

About Cagent Vascular

Cagent Vascular is the first and only company to commercialize an angioplasty balloon with integrated serrations, introducing a new category of endovascular treatment: Serration Remodeling Therapy (SRT). Headquartered in Wayne, PA, our mission is to improve outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) by changing the way physicians treat diseased vessels. Our flagship device, the Serranator® PTA Serration Balloon Catheter, creates controlled micro-fissures in the arterial wall, driving vessel wall remodeling, not just dilation. The result: greater lumen gain, reduced recoil, and improved vessel compliance across lesion morphologies. It's time for a new standard of care. It starts with Serranator.

See more

Latest activity

7 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.